📊 INBX Key Takeaways
Is Inhibrx Biosciences, Inc. (INBX) a Good Investment?
Inhibrx is a pre-revenue stage biotech burning $129.8M annually against only $1.3M in revenue, providing approximately 12 months of cash runway before requiring dilutive capital raises. The debt-to-equity ratio of 12.58x combined with a razor-thin equity base of $8M creates unsustainable financial leverage. Deteriorating net losses expanding 108.3% YoY signal worsening operational efficiency.
Fundamentals are extremely weak: minimal revenue with rapidly widening losses, deeply negative margins, and a very high debt-to-equity ratio on a thin equity base. While liquidity appears solid with substantial cash and a strong current ratio, the operating cash burn approximates the cash balance, implying a short runway without material revenue inflection or new financing. Absent clear evidence of near-term monetization, dilution or balance-sheet stress is likely.
Why Buy Inhibrx Biosciences, Inc. Stock? INBX Key Strengths
- Maintains $124.2M in cash reserves providing near-term liquidity cushion
- Strong current ratio of 3.93x demonstrates adequate working capital management
- Revenue growing 550% YoY shows early commercial traction from base
- Strong liquidity with $124.22M cash and 3.93x current ratio
- Asset-light model with negligible capex
- High YoY revenue growth off a small base (+550%)
INBX Stock Risks: Inhibrx Biosciences, Inc. Investment Risks
- Unsustainable operating cash burn of $129.8M annually with ~12 months of runway remaining
- Extreme financial leverage with debt-to-equity ratio of 12.58x and minimal $8M equity buffer
- Net losses deteriorating 108.3% YoY with no established path to profitability
- Severe, worsening unprofitability (operating and net margins below -10,000%)
- High leverage (12.58x debt/equity) and thin equity base
- Large operating cash burn (-$129.79M) implying limited runway and potential dilution
Key Metrics to Watch
- Monthly cash burn rate and exact timeline to cash depletion
- Revenue ramp trajectory and progress toward positive unit economics
- Timing and terms of required capital raise and shareholder dilution impact
- Operating cash flow (TTM)
- Cash & equivalents
Inhibrx Biosciences, Inc. (INBX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.93x current ratio provides a solid financial cushion.
INBX Profit Margin, ROE & Profitability Analysis
INBX vs Healthcare Sector: How Inhibrx Biosciences, Inc. Compares
How Inhibrx Biosciences, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Inhibrx Biosciences, Inc. Stock Overvalued? INBX Valuation Analysis 2026
Based on fundamental analysis, Inhibrx Biosciences, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Inhibrx Biosciences, Inc. Balance Sheet: INBX Debt, Cash & Liquidity
INBX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Inhibrx Biosciences, Inc.'s revenue has declined by 28% over the 5-year period, indicating business contraction. The most recent EPS of $112.62 reflects profitable operations.
INBX Revenue Growth, EPS Growth & YoY Performance
INBX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$28.7M | $-2.28 |
| Q2 2025 | $100.0K | -$28.7M | $-1.85 |
| Q1 2025 | N/A | -$43.3M | $-2.80 |
| Q3 2024 | N/A | -$43.9M | $-2.84 |
| Q2 2024 | $30.0K | -$47.1M | $-4.31 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Inhibrx Biosciences, Inc. Dividends, Buybacks & Capital Allocation
INBX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Inhibrx Biosciences, Inc. (CIK: 0002007919)
📋 Recent SEC Filings
❓ Frequently Asked Questions about INBX
What is the AI rating for INBX?
Inhibrx Biosciences, Inc. (INBX) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are INBX's key strengths?
Claude: Maintains $124.2M in cash reserves providing near-term liquidity cushion. Strong current ratio of 3.93x demonstrates adequate working capital management. ChatGPT: Strong liquidity with $124.22M cash and 3.93x current ratio. Asset-light model with negligible capex.
What are the risks of investing in INBX?
Claude: Unsustainable operating cash burn of $129.8M annually with ~12 months of runway remaining. Extreme financial leverage with debt-to-equity ratio of 12.58x and minimal $8M equity buffer. ChatGPT: Severe, worsening unprofitability (operating and net margins below -10,000%). High leverage (12.58x debt/equity) and thin equity base.
What is INBX's revenue and growth?
Inhibrx Biosciences, Inc. reported revenue of $1.3M.
Does INBX pay dividends?
Inhibrx Biosciences, Inc. does not currently pay dividends.
Where can I find INBX SEC filings?
Official SEC filings for Inhibrx Biosciences, Inc. (CIK: 0002007919) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is INBX's EPS?
Inhibrx Biosciences, Inc. has a diluted EPS of $-9.04.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is INBX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Inhibrx Biosciences, Inc. has a STRONG SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is INBX stock overvalued or undervalued?
Valuation metrics for INBX: ROE of -1,752.2% (sector avg: 15%), net margin of -10,773.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy INBX stock in 2026?
Our dual AI analysis gives Inhibrx Biosciences, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is INBX's free cash flow?
Inhibrx Biosciences, Inc.'s operating cash flow is $-129.8M, with capital expenditures of $31.0K. FCF margin is -9,986.5%.
How does INBX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -10,773.5% (avg: 12%), ROE -1,752.2% (avg: 15%), current ratio 3.93 (avg: 2).
Is Inhibrx Biosciences, Inc. carrying too much debt?
INBX has a debt-to-equity ratio of 12.58x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 3.93 suggests adequate short-term liquidity.